GSK inks $1.9B Sierra takeover as $3M bet on Gilead castoff turns into blockbuster buyoutnews2022-04-13T09:30:05+00:00April 13th, 2022|FierceBiotech|
Boehringer OKs $100M biobucks deal for hearing loss R&D projectnews2022-04-13T08:42:43+00:00April 13th, 2022|FierceBiotech|
Cimeio exits stealth with $50M, but its cell therapy technology aims to stay incognitonews2022-04-12T21:13:31+00:00April 12th, 2022|FierceBiotech|
Bristol Myers Squibb Foundation unites with Gilead to boost diversity among clinical trial investigatorsnews2022-04-12T19:57:17+00:00April 12th, 2022|FierceBiotech|
AACR: AbbVie’s navitoclax goes after tough blood cancer, not yet reaching overall survival benchmarknews2022-04-12T14:22:13+00:00April 12th, 2022|FierceBiotech|
Carlyle’s acquisition of Abingworth brings $2 billion to fuel life science investmentsnews2022-04-12T14:05:38+00:00April 12th, 2022|FierceBiotech|
Aeglea’s search for signs of efficacy in phase 3 rare disease data impresses investors, sending stock up 30%news2022-04-12T10:11:44+00:00April 12th, 2022|FierceBiotech|
Eyes on the prize: Aurion Biotech raises $120M for ‘global transformation in the cornea’news2022-04-12T01:57:00+00:00April 12th, 2022|FierceBiotech|
Gilead’s CD47 trials freed of FDA hold—for the most partnews2022-04-11T21:23:13+00:00April 11th, 2022|FierceBiotech|
Liver enzyme might hold the secret to new obesity treatmentsnews2022-04-11T20:29:42+00:00April 11th, 2022|FierceBiotech|
